Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd. was f… Read more
Shanghai Rightongene Biotechnology Co. Ltd. A (688217) - Total Assets
Latest total assets as of June 2025: CN¥960.48 Million CNY
Based on the latest financial reports, Shanghai Rightongene Biotechnology Co. Ltd. A (688217) holds total assets worth CN¥960.48 Million CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Rightongene Biotechnology Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Shanghai Rightongene Biotechnology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Rightongene Biotechnology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Rightongene Biotechnology Co. Ltd. A's total assets of CN¥960.48 Million consist of 47.7% current assets and 52.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.1% |
| Accounts Receivable | CN¥165.93 Million | 16.8% |
| Inventory | CN¥43.40 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥41.06 Million | 4.2% |
| Goodwill | CN¥11.12 Million | 1.1% |
Asset Composition Trend (2019–2024)
This chart illustrates how Shanghai Rightongene Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Rightongene Biotechnology Co. Ltd. A's current assets represent 47.7% of total assets in 2024, a decrease from 57.2% in 2019.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2024, down from 19.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 8.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 16.8% of total assets.
Shanghai Rightongene Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Rightongene Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shanghai Rightongene Biotechnology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Rightongene Biotechnology Co. Ltd. A generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanghai Rightongene Biotechnology Co. Ltd. A is currently not profitable relative to its asset base.
Shanghai Rightongene Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.02 | 11.60 | 13.84 |
| Quick Ratio | 13.78 | 10.38 | 12.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥416.41 Million | CN¥ 453.12 Million | CN¥ 487.94 Million |
Shanghai Rightongene Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Rightongene Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.92 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | CN¥985.70 Million |
| Market Capitalization | $128.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Rightongene Biotechnology Co. Ltd. A's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Rightongene Biotechnology Co. Ltd. A's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Rightongene Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Shanghai Rightongene Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥985.70 Million | -5.60% |
| 2023-12-31 | CN¥1.04 Billion | -3.66% |
| 2022-12-31 | CN¥1.08 Billion | +14.39% |
| 2021-12-31 | CN¥947.53 Million | +31.08% |
| 2020-12-31 | CN¥722.85 Million | +10.22% |
| 2019-12-31 | CN¥655.81 Million | -- |